An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001 – a novel irreversible pan-ErbB inhibitor with promising brain penetration – in patients with advanced cancer
Helen Wheeler, Jeffrey Bacha, Sarath Kanekal, Ian Nisbet, Harry Pedersen, Neil Sankar, Wang Shen, Kathy Skoff, Wang Zhen Zhong, Dennis M. Brown
American Association of Cancer Research Annual Meeting. June 2020, Virtual Conference Event.
Leave a Reply